Apr 28, 2020 / 12:00PM GMT
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Blueprint Medicines Conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Mr. Jim Baker, Vice President of Corporate Affairs with -- of Blue Medicine -- Blueprint Medicine. Please go ahead, sir.
Julian Charles Baker -
Thank you, operator. Good morning, everyone, and thank you for joining us today to review the top line results from VOYAGER, our Phase III clinical trial evaluating avapritinib in third-line GIST, which we reported earlier this morning. You can access the press release for the VOYAGER data as well as the slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.
With me today are -- with prepared remarks are Jeff Albers, our Chief Executive Officer; and Dr. Andy Boral, our Chief Medical Officer.
Blueprint Medicines Corp VOYAGER Corporate Call Transcript
Apr 28, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers